Bicara Therapeutics (NASDAQ:BCAX) is developing tumor-targeting bifunctional antibodies, with its lead candidate ficerasfusp alfa designed to address both EGFR and TGF-beta biology in cancer, company ...

A new study published in the Journal American Medical Association showed that patients with an Cystatin C based estimated ...

Co-occurring alterations in EGFR-mutant NSCLC are increasingly detected via broad NGS and may signal aggressive biology, prompting interest in escalation strategies that address concurrent drivers.

Y-complex nucleoporin, Nup107, can regulate ecdysone production by affecting the transcription of Halloween genes and levels of RTK receptor, torso, for the metamorphic transition from larva to pupa.

Sustainability is becoming a commercial requirement in the global events industry, writes John Arvanitakis, chairperson of ...

Sangamo Therapeutics has initiated a rolling Biologics License Application (BLA) submission with the U.S. Food and Drug Administration for its investigational g ...

New for 2026, FORGE Trials introduces an official national qualifier ecosystem, allowing teams competing in partner leagues to earn their place at the championship through structured progression. The ...

As previously presented, gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) and gedatolisib + fulvestrant (“gedatolisib doublet”) ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of science, technology, and medicine news ...

BUFFALO, N.Y. — For decades, pharmacists and medical institutions have relied on the Cockcroft-Gault (C-G) estimated creatinine clearance assessment to determine medication dosing and treatment for ...

Eliana Merle Barclays Bank PLC, Research Division. Hi, everyone. I'm Ellie Merle, one of the biotech analysts here at Barclays. Very excited to have Vertex here with us to discuss ...